Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant
NCT01603108
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
59
Enrollment
OTHER
Sponsor class
Conditions
Hepatitis C
Interventions
DRUG:
Rifaximin
DRUG:
Placebo
Sponsor
Columbia University